In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin

被引:18
作者
Galani, V. J. [1 ,2 ]
Vyas, M.
机构
[1] AR Coll Pharm, Dept Pharmacol, Vallabh Vidyanagar 388120, Gujarat, India
[2] GH Patel Inst Pharm, Vallabh Vidyanagar 388120, Gujarat, India
关键词
Atorvastatin; drug interaction; glimepride; rosuvastatin;
D O I
10.4103/0975-1483.63169
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim of this investigation was to study the in vivo and in vitro drug interaction of glimepride with atorvastatin and rosuvastatin. In vitro drug interaction of glimepride with atorvastatin and rosuvastatin was studied using human pooled liver microsomes and evaluated using high performance liquid chromatography. In vivo pharmacokinetic drug interaction of glimepride (6 mg/kg) in coadministration with atorvastatin (60 mg/kg) and rosuvastatin (60 mg/ kg) were studied in rats and analyzed using liquid chromatography tandem mass spectrometry (LC- MS/MS). In in vitro study, atorvastatin decreased its own metabolism as well as the metabolism of glimepiride. Rosuvastatin coadministration with glimepride reduced the metabolism of glimepride and increased the metabolism of its own. In in vivo study, concentration in plasma, C max, AUC (0- t) and AUC (0-8) (area under the concentration- time curve, AUC) of glimepride was increased significantly in coadministration with atorvastatin whereas there was no significant change was observed in the case of coadministration with rosuvastatin. Half life (T 1/2) and volume of distribution (V d) of glimepride decreased significantly with both atorvastatin and rosuvastatin. Elimination rate constant, K el of glimepride increased significantly with both atorvastatin and rosuvastatin. Clearance (Cl) of glimepride decreased significantly but the decrease was more with atorvastatin than with rosuvastatin. It is concluded that glimepride metabolism is little affected by rosuvastatin in vitro, which agreed with the negligible interaction in in vivo study. Thus, from safety point of view rosuvastatin is better to prescribe as a coadministration therapy with glimepiride. On the other hand, atorvastatin could cause an increase in the bioavailability of glimepride per oral and also significantly decrease the metabolism of glimerpride in in vitro study. This may pose a positive implication in clinical practice.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 15 条
[11]   Lipid control in the management of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians [J].
Snow, V ;
Aronson, MD ;
Hornbake, ER ;
Mottur-Pilson, C ;
Weiss, KB .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (08) :644-649
[12]   Strategies for the management of diabetic dyslipidaemia [J].
Taskinen, MR .
DRUGS, 1999, 58 (Suppl 1) :47-51
[13]   Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians [J].
Vijan, S ;
Hayward, RA .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (08) :650-658
[14]  
White CM, 2002, J CLIN PHARMACOL, V42, P963
[15]   Predicting Drug-Drug Interactions: An FDA Perspective [J].
Zhang, Lei ;
Zhang, Yuanchao ;
Zhao, Ping ;
Huang, Shiew-Mei .
AAPS JOURNAL, 2009, 11 (02) :300-306